Rohit Tripathi, VP of Industry Strategy at RELEX, discusses how pharmaceutical reshoring demands end-to-end capability not ...
The 340B spread mechanism permits covered entities to retain the difference between discounted acquisition cost and commercial or Medicare reimbursement, incentivizing revenue capture rather than ...
Capital continues to flow toward clinical-stage and platform biotech companies, with a wave of new deals, partnerships, and ...
Pharmaceutical Executive releases its 2026 Top 50 company rankings, FDA grants Bristol Myers Squibb's Zenbexus accelerated ...
A funding roundup covers new IPO and Series A raises across Silence Therapeutics, AbCellera, Beyang Therapeutics, and Remepy, Tyler Seville of ADVI examines the policy concerns building around the ...
FDA authorization covers adults ≥50, positioning mFLUSIVA as Moderna’s first mRNA influenza vaccine and expanding its US ...
Last week, reports emerged of a potential merger between AstraZeneca and Bristol Myers Squibb. While a senior source reportedly debunked these rumors days later, the news caused an uproar across the ...
Reauthorization of the PRV program provides multi-year policy certainty and a monetizable voucher that can deliver significant non-dilutive funding upon sale. Absent a PRV-like mechanism, UK ...
In July of this year, Krieger Scientific issued a release addressing the increase in 303 drug warning letters issued by FDA. In 2025, as new leadership took over the agency, FDA sent 303 drug warning ...
A changing of the guard atop Pharm Exec’s latest listing of the top biopharma Rx revenue producers reflects an industry being remade in real time, becoming as much a map of franchise quality and ...
In today's Pharmaceutical Executive Daily, Jazz Pharmaceuticals agrees to acquire Actio Biosciences, Novo Nordisk, Innate Pharma, and Innovent Biologics strike a trio of new partnerships, and a Veeva ...
Consideration includes $820 million upfront and up to $500 million in approval and sales milestones, with financing expected from cash on hand and existing credit facilities. ABS-1230 is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results